

Abstract of the Disclosure

A disease associated with inflammation under non-ischemic conditions is treated or prevented by administering (1) α -melanocyte simulating hormone (α -MSH) and/or a α -MSH equivalent, and/or (2) erythropoietin (EPO) and/or an EPO equivalent, to the individual in need thereof.